Expert Interview
A better understanding of Meniere's disease, current treatment options market and market size. Then specifically discussing the failed Phase 2 study for OTO-104 and likelihood of Phase 3 success.
Ticker(s): OTICENT with significant experience treating Meniere's. Familiarity with the OTO-104 failed Phase 2 data is essential for this expert to qualify.
Please describe your background in Meniere's disease, and how many patients you currently treat.
Added By: joe_mccannHow do you currently treat Meniere's patients? How effective are these treatments, and what do they typically cost both the health care system and your patient?
Added By: joe_mccannHow well identified are Meniere's patients? Is it a homo or heterogeneous disease, and how clear is a diagnosis?
Added By: joe_mccannWhat is your initial impression of the OTO-104 Phase 2 data and why might the 3rd month have lead to missing the primary endpoint?
Added By: joe_mccannWhat do you make of the company's new Phase 3 trial design and how will it help them succeed in the newest trials?
Added By: joe_mccannWhat is the hurdle in this Phase 3 trial for clinical relevance in your opinion rather than just statistical relevance?
Added By: joe_mccannWhat do you think the probability is that OTO-104 will be standard of care for Meniere's Disease in 2020 and beyond?
Added By: joe_mccannWhat questions am I missing on this drug and development plan in general?
Added By: joe_mccannAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
- Top line Phase 3 results for OTO-104 in Meniere's disease anticipated OTIC Occurred On: Aug 30, 2017
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
